Buscar
Longeveron Inc
LGVNAñadir a la lista de seguimiento
2.600USD
0.0000.00%
Horarios del mercado 09/23, 15:34（ET）
82.16MCap. mercado
PérdidaP/E TTM
Acerca de Longeveron Inc Compañía
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Perfil de Longeveron Inc
Símbolo de cotizaciónLGVN
Nombre de la empresaLongeveron Inc
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoPowell (Than)
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 12
Dirección1951 NW 7th Ave
CiudadMIAMI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33136
Teléfono13053027158
Sitio Webhttps://www.longeveron.com/
Símbolo de cotizaciónLGVN
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoPowell (Than)
Ejecutivos de Longeveron Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
54.25K
+52.72%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Longeveron Inc?
Los cinco principales accionistas de Longeveron Inc son: Dr. Nataliya Agafonova, M.D.
¿Cuántas instituciones poseen acciones de Longeveron Inc (LGVN)?
A fecha de 2026Q1, 62 instituciones poseen acciones de Longeveron Inc, con un valor de mercado combinado de aproximadamente 2.25M, lo que representa el 8.08% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1131825.00.